Equities

Carna Biosciences Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4572:TYO

Carna Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)319.00
  • Today's Change-6.00 / -1.85%
  • Shares traded285.90k
  • 1 Year change+6.69%
  • Beta0.8600
Data delayed at least 15 minutes, as of Feb 20 2026 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Carna Biosciences, Inc. is a Japan-based company mainly engaged in the drug development support business and the drug development business. The Company operates in two business segments. The Drug Development Support segment is engaged in sales of protein kinase, development of assay, as well as provision of profiling and screening service. The Drug Development segment is engaged in the research and development of kinase inhibitors and other drugs.

  • Revenue in JPY (TTM)579.06m
  • Net income in JPY-2.17bn
  • Incorporated2003
  • Employees63.00
  • Location
    Carna Biosciences IncKIBC Bldg. 5115-5-2 Minatojima-MinamimachiChuo-kuKOBE-SHI 650-0047JapanJPN
  • Phone+81 783027039
  • Fax+81 783026665
  • Websitehttps://www.carnabio.com/japanese
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
FunPep Co Ltd314.00k-1.91bn3.77bn15.00--2.58--12,014.12-51.03-51.030.008336.090.0001-------75.09-37.74-92.91-41.17-----608,766.90-4,142.723.71-------94.88-36.20-115.00------
Human Metabolome Technologies Inc1.43bn207.06m4.35bn62.0020.752.2913.633.0435.4235.42248.83321.250.623710.294.9123,060,290.009.0310.5410.9813.5960.4866.6514.4817.245.13391.350.055520.988.125.405.42--33.68--
Ribomic Inc750.00k-1.04bn4.56bn25.00--1.42--6,085.26-22.23-22.230.015959.350.0002--0.017330,000.00-31.47-29.95-32.94-31.15-----138,954.00-2,725.9520.66--0.00-----55.550.5173---6.86--
Modalis Therapeutics Corp0.00-2.15bn5.07bn14.00--1.80-----28.13-28.130.0032.230.00-------64.69-47.62-67.23-49.48-------22,365.60-------------63.34---68.51--
D.Western Therapeutics Institute Inc387.62m-632.09m5.53bn21.00--3.85--14.28-13.31-13.318.0926.460.20190.41153.53---32.93-28.15-36.09-30.6889.9792.09-163.07-155.999.48--0.2966---17.801.7451.01---11.74--
Carna Biosciences, Inc.579.06m-2.17bn6.24bn63.00--20.12--10.77-113.62-113.6230.3016.160.28941.246.17---108.53-37.21-120.28-41.9867.0386.49-375.00-118.286.08-75.550.6979---8.99-12.570.3262---33.02--
TMS Co Ltd0.00-693.96m6.41bn18.00--2.31-----15.47-15.470.0060.920.00-------24.01---24.96----------30.41------------------
Cyfuse Biomedical KK-100.00bn-100.00bn6.61bn21.00--2.31----------286.90-----------13.87---16.49--68.61---178.864.44--0.3224--324.2710.9412.43--182.58--
Noile-Immune Biotech Inc5.00m-793.54m6.80bn25.00--1.73--1,359.68-18.33-18.330.115590.800.0011--0.1129---18.01-17.82-18.31-18.34-----15,870.72-385.4153.51-------34.10-44.7717.72------
Tsubota Laboratory Inc710.56m-398.77m6.91bn17.00--6.25--9.73-15.53-15.5327.5542.860.35940.452250.4641,797,700.00-20.170.1041-29.560.151781.6571.43-56.120.22162.60--0.06340.00101.4925.17132.08132.7026.42--
Linical Co Ltd9.32bn-1.77bn7.82bn598.00--1.26--0.8389-78.51-78.51412.61251.020.5937--3.6215,584,280.00-11.302.59-20.504.1917.4829.24-19.033.74---192.930.293377.26-15.20-0.9283-259.37---42.014.24
OncoTherapy Science, Inc.784.25m-881.65m7.91bn47.00--3.70--10.09-2.93-2.932.605.680.42248.388.7216,686,090.00-47.48-63.66-56.22-77.433.63-0.3852-112.42-184.758.13-832.790.0043--22.9318.8636.71---70.80--
PRISM BioLab Co Ltd684.61m-927.75m8.16bn35.00--3.35--11.92-25.27-25.2718.6466.060.1886--8.7919,560,140.00-25.55---32.06--38.47---135.52-----77.050.00--121.62--20.56------
Medinet Co Ltd787.09m-1.36bn8.27bn107.00--2.39--10.50-5.12-5.122.9712.950.170111.083.007,355,991.00-29.29-22.42-31.04-23.6413.5817.68-172.25-173.5911.33--0.00--5.440.6867-6.67--10.06--
Chiome Bioscience Inc593.29m-982.78m8.61bn47.00--7.56--14.52-14.48-14.488.7416.390.28284.979.64---46.84-52.22-59.06-64.4159.9357.59-165.65-174.883.99-1,177.610.1891---24.024.293.72------
Chordia Therapeutics Inc0.00-1.46bn8.82bn20.00--3.70-----21.23-21.230.0032.670.00----0.00-46.77---49.97-------------222.950.00------2.26------
Data as of Feb 20 2026. Currency figures normalised to Carna Biosciences Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

8.05%Per cent of shares held by top holders
HolderShares% Held
Athos Capital Ltd.as of 11 Oct 20241.40m7.31%
PineBridge Investments Japan Co., Ltd.as of 30 Jun 2025142.10k0.74%
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.